Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tjønnfjord GE, Itälä-Remes MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH, Niemann CU. Vojdeman FJ, et al. Among authors: doorduijn jk. Leuk Lymphoma. 2017 Oct;58(10):2356-2362. doi: 10.1080/10428194.2017.1285027. Epub 2017 Feb 7. Leuk Lymphoma. 2017. PMID: 28278728 Free PMC article.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Spanjaart AM, Pennings ERA, Mutsaers PGNJ, van Dorp S, Jak M, van Doesum JA, de Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, van der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, van Meerten T, Kersten MJ; Dutch CAR-T Tumorboard Consortium. Spanjaart AM, et al. Among authors: doorduijn jk. Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334. Cancers (Basel). 2023. PMID: 37686611 Free PMC article.
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Le Gouill S, Długosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain P, Calvo R, Tao L, Wang M. Le Gouill S, et al. Among authors: doorduijn jk. Haematologica. 2024 Jan 1;109(1):343-350. doi: 10.3324/haematol.2022.282469. Haematologica. 2024. PMID: 37470152 Free PMC article. No abstract available.
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NA, Luijks DM, Eldering E, van Oers MH. Kater AP, et al. Among authors: doorduijn jk. Leuk Res. 2014 Jan;38(1):34-41. doi: 10.1016/j.leukres.2013.10.004. Epub 2013 Oct 28. Leuk Res. 2014. PMID: 24238639 Clinical Trial.
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M. Hoster E, et al. J Clin Oncol. 2014 May 1;32(13):1338-46. doi: 10.1200/JCO.2013.52.2466. Epub 2014 Mar 31. J Clin Oncol. 2014. PMID: 24687837
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MC, Doorduijn J, Ghidey Alemayehu W, van Oers MH. Geisler CH, et al. Blood. 2014 May 22;123(21):3255-62. doi: 10.1182/blood-2014-01-547737. Epub 2014 Apr 15. Blood. 2014. PMID: 24735962 Free article. Clinical Trial.
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.
Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Hoster E, et al. Leukemia. 2016 Jun;30(6):1428-30. doi: 10.1038/leu.2015.322. Epub 2015 Nov 24. Leukemia. 2016. PMID: 26598017 No abstract available.
The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.
Vojdeman FJ, Van't Veer MB, Tjønnfjord GE, Itälä-Remes M, Kimby E, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MC, van Oers MH, Geisler CH. Vojdeman FJ, et al. Among authors: doorduijn jk. Leuk Lymphoma. 2017 Mar;58(3):594-600. doi: 10.1080/10428194.2016.1213831. Epub 2016 Aug 2. Leuk Lymphoma. 2017. PMID: 27484290
98 results